الإعلام
Biotricity Inc. (Biotricity) today announced that the company is expected to join the Russell Microcap® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, 2022. Membership in the Russell Microcap® Index, which remains in place for one year, includes inclusion in the appropriate growth and value style indexes.
Wedge Networks Inc. (Wedge) is invited to join MobilityXlab, a collaboration hub founded in 2017 by global companies to create and innovate future mobility solutions. Wedge will participate to co-create solutions for safe and secure mobility in partnership with seven world-leading industry partners: CEVT, Ericsson, Polestar, Veoneer, Volvo Cars, Volvo Group, and Zenseact.
Wedge Networks Inc. (Wedge) is introducing a new generation of its Intelligent Web Shield™ (IWS) solution available to all customers and partners using WedgeARP™ v2.6 and above to support up and coming SASE use cases. The ever-expanding SASE market is witnessing novel use cases such as 5G Edge/MEC services, smart infrastructure, smart manufacturing and CAV/ITS all of which require zero trust for both access and network traffic at the edge.
Wedge Networks Inc. (Wedge) announced that the United States Patent and Trademark Office (USPTO) has awarded its technology with U.S. Patent 11,349,852, ascertaining Wedge Network’s unique value proposition and innovation. This invention builds on Wedge’s previous network-based content inspection (NBCI) patent – USPTO #7,630,379.
Biotricity Inc. (Biotricity) today provided an update for its shareholders by Chief Executive Officer Waqaas Al-Siddiq, Ph.D., that discusses recent company achievements and strategic initiatives to position the business for strong 2022 results, increasing scale and accelerating growth into 2023.
Biotricity Inc. (Biotricity) will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since late-February 2022.
